Brain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Clin Cancer Res. 2011 Oct 1;17(19):6109-11. doi: 10.1158/1078-0432.CCR-11-1853. Epub 2011 Aug 18.
Targeting angiogenesis in glioblastoma rapidly reduces vascular permeability and contrast enhancement on MRI and prolongs progression-free survival. The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy.
针对胶质母细胞瘤的血管生成治疗可迅速降低 MRI 上的血管通透性和对比增强，并延长无进展生存期。然而，贝伐珠单抗和其他抗血管生成药物的长期疗效有限，这是由于迅速产生耐药性。改变给药方案可能是延长治疗效果的一种机制。
